MYO Myomo Inc.
$1.30▲ +0.00%
Healthcare
Other
Volume 324.9K
Avg Volume (10D) 377.5K
Key Metrics & Fundamentals
Market Cap
$51.49M
P/E Ratio
–
Div Yield
–%
52W Range
0.61 - 1.89
% vs 50 MA
1.47%
% vs 200 MA
29.61%
RSI-14
44.4
MACD Histogram
-0.0500
Beta (1Y vs SPY)
2.07
Free Cash Flow
-$2.02M
Gross Rev
$11.70M
Gross Profit
$8.44M
EBITDA
-$1.69M
COGS
$3.26M
Operating Exp
$10.70M
Operating Income
-$2.25M
EBIT
-$2.25M
Pretax Income
-$3.99M
Net Income
-$4.02M
EPS (Diluted)
-0.09
Price & Volume History
Loading chart…
Recent News
Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Business Wire · Sep 1, 2026 8:05 PM
Myomo Q2 Earnings Call Highlights
MarketBeat · Aug 9, 2026 7:04 PM
Myomo Inc (MYO) (Q2 2026) Earnings Call Highlights: Record Orders and Margin Expansion Drive ...
GuruFocus.com · Aug 6, 2026 5:11 AM
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Zacks · Aug 6, 2026 12:35 AM
Myomo Reports Second Quarter 2026 Financial and Operating Results
Business Wire · Aug 5, 2026 8:05 PM
Myomo to Report Second Quarter 2026 Financial Results on August 5
Business Wire · Jul 29, 2026 8:05 PM
iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today
ACCESS Newswire · Jun 23, 2026 12:15 PM
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026
ACCESS Newswire · Jun 18, 2026 1:00 PM
Myomo Announces Participation in iAccess Alpha Virtual Best Ideas Summer Investment Conference
Business Wire · Jun 16, 2026 8:05 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See MYO's money flow as a full page
Social Sentiment
No Reddit posts found for MYO.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.